Novartis Seeks To Aquire Avidity For $12 Billion

Novartis just rang the bell on its biggest deal in a decade, agreeing to buy San Diego–based Avidity Biosciences for $72 a share in cash — about a $12 billion tab and a 46% premium to Friday’s close. It’s a straight-line bet that RNA therapies for rare neuromuscular diseases aren’t just cool science, they’re future revenue streams big enough to make patent cliffs feel like speed bumps.

Avidity brings late-stage programs that target genetically defined muscle disorders, plus a delivery platform designed to get RNA medicines where they need to go (muscle and related tissues) without losing the package in transit. Novartis’ own statement frames the deal as a way to “strengthen its late-stage pipeline,” essentially stapling Avidity’s precision muscle playbook onto a Big Pharma commercial engine. This deal is meant to turn promising biology into industrial-scale launches.

Before closing, Avidity will spin off its early-stage precision cardiology programs into a separate “SpinCo,” letting Novartis focus on the near-commercial muscle assets while the earlier science gets its own runway. Strategically, Novartis says the acquisition should nudge its sales growth rate higher through 2029—even if profitability blinks for a bit during integration—which is CEO-speak for “yes, we brought our own DCF.”

Novartis's strategy is beginning to resemble something like Pharma takeout: when you don’t have enough time to cook the next growth pillar from scratch, you tip well and let a Nasdaq ticker deliver it hot. The market’s punchline is serious, though. With boards approving the deal and a premium priced in, biotech M&A season remains open—proof that in healthcare, sometimes the quickest route to innovation is a wire transfer.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726